News

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted

The Swiss pharmaceutical giant Roche is planning a fundamental restructuring of its capital structure, marking a significant departure from outdated financial instruments. The company's board will

The Swiss pharmaceutical giant Roche is planning a fundamental restructuring of its capital structure, marking a significant departure from outdated financial instruments. The company's board will

Pharmaceutical giant Roche faces significant setbacks after its promising COPD drug candidate Astegolimab failed to meet primary endpoints in the crucial Phase III ARNASA study. The experimental

Pharmaceutical giant Roche faces significant setbacks after its promising COPD drug candidate Astegolimab failed to meet primary endpoints in the crucial Phase III ARNASA study. The experimental

Novartis delivered an impressive start to 2025, with first-quarter figures substantially surpassing market forecasts. The Swiss pharmaceutical giant reported revenue of $13.2 billion, representing a

Novartis delivered an impressive start to 2025, with first-quarter figures substantially surpassing market forecasts. The Swiss pharmaceutical giant reported revenue of $13.2 billion, representing a

Novartis shares experienced a notable decline on Friday at the Swiss SIX exchange, falling 0.7 percent to close at 96.25 CHF. The pharmaceutical stock opened at 96.52 CHF before touching a daily low

Novartis shares experienced a notable decline on Friday at the Swiss SIX exchange, falling 0.7 percent to close at 96.25 CHF. The pharmaceutical stock opened at 96.52 CHF before touching a daily low

Roche's stock has displayed a mixed performance in recent trading sessions. On Thursday afternoon, shares initially gained 0.5 percent to reach 304.70 CHF on the SIX Swiss Exchange, even touching a

Roche's stock has displayed a mixed performance in recent trading sessions. On Thursday afternoon, shares initially gained 0.5 percent to reach 304.70 CHF on the SIX Swiss Exchange, even touching a

The Swiss pharmaceutical giant has experienced a notable stock price increase following the unveiling of its groundbreaking DNA sequencing technology. The innovative method, dubbed "Sequencing by

The Swiss pharmaceutical giant has experienced a notable stock price increase following the unveiling of its groundbreaking DNA sequencing technology. The innovative method, dubbed "Sequencing by

The pharmaceutical giant Roche demonstrated market resilience as its stock recorded a modest uptick, closing with a 0.6 percent gain. The shares reached an intraday peak of 289.80 CHF, highlighting

The pharmaceutical giant Roche demonstrated market resilience as its stock recorded a modest uptick, closing with a 0.6 percent gain. The shares reached an intraday peak of 289.80 CHF, highlighting

The Novartis stock demonstrated robust performance on Monday at the Swiss Stock Exchange SIX, marking a significant upward trajectory throughout the trading session. The pharmaceutical giant's

The Novartis stock demonstrated robust performance on Monday at the Swiss Stock Exchange SIX, marking a significant upward trajectory throughout the trading session. The pharmaceutical giant's

Novartis experienced a notable decline on the Swiss SIX exchange Friday, with shares falling 0.4 percent to close at 97.31 CHF after touching a daily low of 96.87 CHF. The stock's movement attracted

Novartis experienced a notable decline on the Swiss SIX exchange Friday, with shares falling 0.4 percent to close at 97.31 CHF after touching a daily low of 96.87 CHF. The stock's movement attracted

Roche's stock demonstrated remarkable momentum on Friday at the Swiss SIX Exchange, climbing 0.8 percent to reach 290.10 CHF amid robust trading activity. The pharmaceutical giant's shares witnessed

Roche's stock demonstrated remarkable momentum on Friday at the Swiss SIX Exchange, climbing 0.8 percent to reach 290.10 CHF amid robust trading activity. The pharmaceutical giant's shares witnessed

Novartis shares displayed volatile trading patterns on Monday at the Swiss SIX exchange, reflecting dynamic market sentiment throughout the session. Opening at CHF 94.86, the stock initially dipped